January 2, 2018 / 12:11 PM / a year ago

BRIEF-Protalix Biotherapeutics Reports Positive Interim Data From Phase II Clinical Trial Of Oprx-106

Jan 2 (Reuters) - Protalix Biotherapeutics Inc:

* PROTALIX BIOTHERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM PHASE II CLINICAL TRIAL OF OPRX-106 IN PATIENTS WITH ULCERATIVE COLITIS

* PROTALIX BIOTHERAPEUTICS - ‍TREATMENT WAS WELL TOLERATED AND MAJORITY OF ADVERSE EVENTS HAVE BEEN MILD TO MODERATE AND TRANSIENT IN NATURE IN STUDY​

* PROTALIX BIOTHERAPEUTICS - EXPECTS TO REPORT FULL RESULTS FROM PHASE II CLINICAL TRIAL OF OPRX-106 BY END OF Q1 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below